PI-based initial therapy in adults

For protease inhibitor (PI)–based initial antiretroviral therapy in adults, use¹:

1tenofovir alafenamide+emtricitabine+cobicistat+darunavir (Symtuza) 10 mg+200 mg+150 mg+800 mg orally, daily. For dosage adjustment in adults with kidney impairment, see tenofovir alafenamide+emtricitabine+cobicistat+darunavir dosage adjustment. For practice points for initiation of therapy, see Practice points for initial antiretroviral therapy tenofovir alafenamide + emtricitabine + cobicistat + darunavir (Symtuza) tenofovir alafenamide+emtricitabine+cobicistat+darunavir (Symtuza) tenofovir alafenamide+emtricitabine+cobicistat+darunavir (Symtuza)

OR (as a 2-tablet regimen)

2darunavir+cobicistat (Prezcobix) 800 mg+150 mg orally, daily. For practice points for initiation of therapy, see Practice points for initial antiretroviral therapy darunavir + cobicistat (Prezcobix) darunavir+cobicistat (Prezcobix) darunavir+cobicistat (Prezcobix)

PLUS EITHER

1abacavir+lamivudine (Kivexa) 600 mg+300 mg orally, daily. For dosage adjustment in adults with kidney impairment, see abacavir+lamivudine dosage adjustment. For practice points for initiation of therapy, see Practice points for initial antiretroviral therapy abacavir + lamivudine (Kivexa) abacavir+lamivudine (Kivexa) abacavir+lamivudine (Kivexa)

OR

1emtricitabine+tenofovir alafenamide (Descovy) 200 mg+10 mg orally, daily. For dosage adjustment in adults with kidney impairment, see emtricitabine+tenofovir alafenamide dosage adjustment. For practice points for initiation of therapy, see Practice points for initial antiretroviral therapy. emtricitabine + tenofovir alafenamide (Descovy) emtricitabine+tenofovir alafenamide (Descovy) emtricitabine+tenofovir alafenamide (Descovy)

¹ Brand names are examples only; other brands may be available.Return